newsfilter.io
Aug 7, 2026, 8:35 AM ETHealthcare

Xenetic Biosciences — Second Quarter 2026 Earnings Summary

XBIOXENETIC BIOSCIENCES INC
Source

Financial Performance

  • Royalty revenue for the three months ended June 30, 2026, increased approximately 12% to approximately $0.7 million, compared to approximately $0.6 million in the comparable quarter of 2025, driven by higher revenue under the sublicense agreement with Takeda Pharmaceuticals Co. Ltd.
  • Research and development expenses for the quarter decreased approximately 16% to approximately $0.6 million, compared to approximately $0.7 million in the prior-year period, due to lower manufacturing development efforts and reduced consulting costs.
  • General and administrative expenses increased approximately 64% to approximately $1.1 million, compared to approximately $0.7 million in the comparable quarter of 2025, primarily attributed to higher legal expenses associated with the strategic review process.
  • Net loss for the quarter ended June 30, 2026, was approximately $0.9 million, compared to approximately $0.7 million for the same period in 2025.
  • The Company held approximately $6.5 million in cash and cash equivalents at the end of the second quarter of 2026, down from approximately $7.9 million as of December 31, 2025.
  • Approximately $1.5 million in royalty revenue was generated during the first six months of 2026.

Business Segments and Product Lines

  • Positive preclinical and translational data presented at the 2026 ASCO Annual Meeting demonstrated that DNase I significantly enhanced CAR T-cell expansion, persistence, tumor control, and survival across preclinical hematologic cancer models.
  • Collaboration partner PeriNess Ltd. received approval from the Israeli Ministry of Health and respective Institutional Review Boards to conduct an investigator-initiated exploratory study evaluating systemic recombinant human DNase I in combination with anti-CD19 CAR T-cell therapy in patients with large B-cell lymphoma at Tel Aviv Sourasky Medical Center.
  • The Company continues to advance its proprietary DNase platform as an adjunctive therapy targeting neutrophil extracellular traps (NETs) to improve outcomes for existing treatments, including immunotherapies.
  • Current focus includes advancing the systemic DNase program into the clinic for pancreatic carcinoma and locally advanced or metastatic solid tumors.

Management Commentary and Tone

  • James Parslow, Interim Chief Executive Officer and Chief Financial Officer, stated that the Company continues to generate strong translational data supporting DNase I as a differentiated adjunct therapy designed to improve the efficacy and durability of CAR T-cell therapies.
  • Management highlighted a disciplined approach involving prudent capital allocation to inform future clinical development and advance the ongoing strategic review process.
  • The Company believes its combination of royalty revenue from the legacy PolyXen technology and scientific foundation positions it to pursue long-term opportunities creating value for patients and shareholders.

Risks and Challenges

  • The press release notes a strategic review process being conducted by the Board and a special independent committee, with risks including the possibility that the Board may decide not to undertake a strategic alternative, the inability to consummate a proposed alternative, and potential disruption to business operations or adverse effects on stock price.
  • Risks include unexpected costs from manufacturing and collaboration agreements, licensing of the DNase platform, and uncertainty regarding future financial performance following licensing.
  • Potential failure to realize the anticipated potential of DNase or PolyXen technologies, inability to obtain funding, and risks related to regulatory processes, manufacturing issues, patent positions, and litigation are identified.
  • External factors such as public health issues, geopolitical events (conflicts in Ukraine and the Middle East), and shareholder activism could materially affect actual results.

Other Key Points

  • The Company is executing a long-term strategy to advance its proprietary DNase platform through scientific collaboration and translational research.
  • Ongoing generation of translational data is designed to support future clinical development and deepen the understanding of DNase I-mediated NET targeting.
  • Continued royalty generation provides recurring, non-dilutive funding to support investment in core development programs.